Skip to content
DataLookout
Menu

MAHOGANYNCT05100862

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 65 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites revised (264)
  2. Notable Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 3 of 11 entries
    • Study sites revised (264)
  3. Minor Study sites: 266 to 264v63
  4. Minor Study sites: 268 to 266v62
  5. Minor Study sites: 270 to 268v61
  6. Minor Trial sites expanded: 257 → 270 locationsv60
  7. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Trial sites reduced: 277 → 257 locations
    • Enrollment target: estimated 780 to confirmed 799
    v59
  8. Minor Study sites revised (277)v58
  9. Notable Sponsor changed: BeiGene to BeOne Medicines
    • Site details revised at 8 of 277 sites
    v57
  10. Minor Site details revised at 2 of 277 sitesv56
  11. Minor Study sites revised (277)v55
  12. Minor Site details revised at 1 of 277 sitesv54
  13. Minor Study sites revised (277)v53
  14. Minor Study sites: 258 to 277v52
  15. Minor Study sites: 259 to 258v51
  16. Minor Site details revised at 2 of 259 sitesv50
  17. Minor Study sites: 256 to 259v49
  18. Minor Study sites: 259 to 256v48
  19. Minor Study sites: 265 to 259v47
  20. Minor Site details revised at 27 of 265 sitesv46
  21. Minor Study sites: 289 to 265v45
  22. Minor Site details revised at 10 of 289 sitesv44
  23. Minor Study sites: 291 to 289v43
  24. Minor Study sites: 294 to 291v42
  25. Minor Enrollment target: 750 to 780v41
  26. Minor Study sites: 287 to 294v40
  27. Minor Study sites: 290 to 287v39
  28. Minor Study sites: 298 to 290v38
  29. Minor Study sites: 300 to 298v37
  30. Minor Study sites: 295 to 300v36
  31. Minor Study sites: 294 to 295v35
  32. Minor Site details revised at 1 of 294 sitesv34
  33. Minor Study sites: 175 to 294v33
  34. Minor Study sites: 237 to 175v32
  35. Minor Study sites: 253 to 237v31
  36. Minor Study sites: 244 to 253v30
  37. Notable Eligibility criteria expanded, about 22 words
    • Study sites: 236 to 244
    v29
  38. Minor Study sites: 228 to 236v28
  39. Minor Study sites: 224 to 228v27
  40. Minor Study sites: 216 to 224v26
  41. Minor Study sites: 203 to 216v25
  42. Minor Study sites: 181 to 203v24
  43. Minor Study sites: 171 to 181v23
  44. Minor Study sites: 154 to 171v22
  45. Minor Study sites: 137 to 154
    • Primary completion date: Aug 2028 to Jul 2028
    • Study completion date: Jun 2029 to Jun 2030
    v21
  46. Minor Study sites: 115 to 137v20
  47. Minor Study sites: 87 to 115v19
  48. Minor Study sites: 71 to 87v18
  49. Minor Study sites: 54 to 71v17
  50. Minor Study sites: 43 to 54v16
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)
Timeframe: Approximately 78 months

Secondary (11)

Progression-free Survival As Determined By Investigator Assessment
Duration Of Response As Determined By BIRC And By Investigator Assessment
Overall Response Rate As Determined By BIRC And By Investigator Assessment
Complete Response Rate As Determined By BIRC And By Investigator Assessment
Time To Response As Determined By BIRC And By Investigator Assessment
Show 6 moreShow less
Time to Next Ant-Lymphoma Treatment
Overall Survival
Health-related Quality Of Life (HRQoL) Using EORTC QLQ-C30)
HRQoL Using European Quality of Life 5 Dimension 5 Level Questionnaire [EQ 5D 5L)
HRQoL Using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 [FLymSI 18)
Number of Participants Experiencing Adverse Events (AEs)

Arms and interventions

Follicular Lymphoma Arm A: Zanubrutinib plus ObinutuzumabExperimental

Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

Follicular Lymphoma Arm B: Lenalidomide plus RituximabActive comparator

Participants will receive lenalidomide and rituximab.

Marginal Zone Lymphoma Arm C: Zanubrutinib plus RituximabExperimental

Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

Marginal Zone Lymphoma Arm D: Lenalidomide plus RituximabActive comparator

Participants will receive lenalidomide and rituximab.

Drugs: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab

Sites

264 sites in 28 countries

United States 50, China 38, Brazil 22, Australia 17, Spain 16, Japan 13, South Korea 13, Canada 10, Italy 10, Poland 9, United Kingdom 9, France 8, Israel 7, Austria 5, Turkey (Türkiye) 5, Belgium 4, Romania 4, Greece 3, Portugal 3, Switzerland 3, Argentina 2, Bulgaria 2, Czechia 2, Germany 2, Ireland 2, Puerto Rico 2, South Africa 2, Georgia 1